Personalized Depression Treatment Explained In Fewer Than 140 Characte…
Marcus Penson
2024.09.20 17:16
2
0
본문
Personalized bipolar depression treatment Treatment
Traditional therapies and medications don't work for a majority of people suffering from depression. Personalized treatment could be the solution.
Cue is an intervention platform that converts sensor data collected from smartphones into personalized micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each subject, using Shapley values, in order to understand their feature predictors. This revealed distinct features that changed mood in a predictable manner over time.
Predictors of Mood
Depression is one of the world's leading causes of mental illness.1 Yet, only half of those who have the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to identify and treat patients who have the highest chance of responding to specific treatments.
Personalized depression treatment can help. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from which treatments. Two grants worth more than $10 million will be used to identify biological and behavior factors that predict response.
The majority of research into predictors of depression treatment effectiveness (https://cooklimit6.bravejournal.net/) has been focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological indicators such as neuroimaging and genetic variation.
Very few studies have used longitudinal data in order to determine mood among individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is important to devise methods that allow for the analysis and measurement of individual differences in mood predictors and treatment effects, for instance.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to detect patterns of behavior and emotions that are unique to each person.
In addition to these modalities the team also developed a machine-learning algorithm to model the changing predictors of each person's depressed mood. The algorithm blends the individual characteristics to create a unique "digital genotype" for each participant.
This digital phenotype has been correlated with CAT DI scores, a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.
Predictors of symptoms
Depression is the leading cause of disability around the world1, however, it is often misdiagnosed and untreated2. Depressive disorders are often not treated because of the stigma that surrounds them and the absence of effective treatments.
To assist in individualized treatment, it is crucial to identify the factors that predict symptoms. However, the methods used to predict symptoms rely on clinical interview, which is not reliable and only detects a small number of symptoms associated with depression.2
Using machine learning to combine continuous digital behavioral phenotypes captured by smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, CAT-DI) with other predictors of symptom severity can improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of unique behaviors and activity patterns that are difficult to record with interviews.
The study included University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA inpatient depression treatment centers Grand Challenge. Participants were sent online for support or clinical care according to the degree of their depression. Patients with a CAT DI score of 35 65 were given online support by an instructor and those with scores of 75 patients were referred to psychotherapy in person.
At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial characteristics. The questions covered age, sex and education, financial status, marital status, whether they were divorced or not, their current suicidal ideas, intent or attempts, and how depression is treated often they drank. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every week for those who received online support and weekly for those receiving in-person care.
Predictors of shock treatment for depression Reaction
A customized treatment for depression is currently a top research topic and many studies aim at identifying predictors that allow clinicians to identify the most effective drugs for each person. In particular, pharmacogenetics identifies genetic variations that affect the way that the body processes antidepressants. This lets doctors choose the medications that will likely work best for every patient, minimizing time and effort spent on trial-and error treatments and avoid any negative side effects.
Another promising approach is building models for prediction using multiple data sources, including clinical information and neural imaging data. These models can be used to determine the most appropriate combination of variables that are predictive of a particular outcome, like whether or not a drug is likely to improve symptoms and mood. These models can be used to determine the response of a patient to a treatment they are currently receiving, allowing doctors to maximize the effectiveness of the treatment currently being administered.
A new generation of studies utilizes machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have been proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming popular in psychiatry, and it is expected that they will become the standard for the future of clinical practice.
The study of depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that the disorder is linked with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.
Internet-delivered interventions can be a way to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a web-based program was more effective than standard care in reducing symptoms and ensuring a better quality of life for those with MDD. In addition, a controlled randomized study of a customized treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a large number of participants.
Predictors of adverse effects
A major issue in personalizing depression treatment involves identifying and predicting the antidepressant medications that will have very little or no side effects. Many patients experience a trial-and-error method, involving several medications prescribed before finding one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting method to choose antidepressant drugs that are more efficient and targeted.
There are a variety of predictors that can be used to determine which antidepressant should be prescribed, such as gene variations, phenotypes of patients like gender or ethnicity and co-morbidities. However it is difficult to determine the most reliable and valid factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of much larger samples than those typically enrolled in clinical trials. This is because it may be more difficult to identify moderators or interactions in trials that only include one episode per participant rather than multiple episodes over time.
Furthermore the prediction of a patient's response to a particular medication will also likely require information about the symptom profile and comorbidities, and the patient's personal experiences with the effectiveness and tolerability of the medication. Presently, only a handful of easily measurable sociodemographic and clinical variables appear to be correlated with the response to MDD factors, including age, gender race/ethnicity, SES, BMI and the presence of alexithymia and the severity of depressive symptoms.
There are many challenges to overcome in the application of pharmacogenetics in the treatment resistant depression treatment of depression. It is crucial to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an accurate definition of a reliable indicator of the response to treatment. In addition, ethical concerns, such as privacy and the appropriate use of personal genetic information, must be carefully considered. In the long term the use of pharmacogenetics could offer a chance to lessen the stigma that surrounds mental health care and improve treatment outcomes for those struggling with depression. However, as with all approaches to psychiatry, careful consideration and planning is essential. The best option is to offer patients various effective depression medications and encourage them to talk openly with their doctors about their concerns and experiences.
Traditional therapies and medications don't work for a majority of people suffering from depression. Personalized treatment could be the solution.
Cue is an intervention platform that converts sensor data collected from smartphones into personalized micro-interventions that improve mental health. We looked at the best-fitting personal ML models to each subject, using Shapley values, in order to understand their feature predictors. This revealed distinct features that changed mood in a predictable manner over time.
Predictors of Mood
Depression is one of the world's leading causes of mental illness.1 Yet, only half of those who have the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to identify and treat patients who have the highest chance of responding to specific treatments.
Personalized depression treatment can help. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from which treatments. Two grants worth more than $10 million will be used to identify biological and behavior factors that predict response.
The majority of research into predictors of depression treatment effectiveness (https://cooklimit6.bravejournal.net/) has been focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological indicators such as neuroimaging and genetic variation.
Very few studies have used longitudinal data in order to determine mood among individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is important to devise methods that allow for the analysis and measurement of individual differences in mood predictors and treatment effects, for instance.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to detect patterns of behavior and emotions that are unique to each person.
In addition to these modalities the team also developed a machine-learning algorithm to model the changing predictors of each person's depressed mood. The algorithm blends the individual characteristics to create a unique "digital genotype" for each participant.
This digital phenotype has been correlated with CAT DI scores, a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.
Predictors of symptoms
Depression is the leading cause of disability around the world1, however, it is often misdiagnosed and untreated2. Depressive disorders are often not treated because of the stigma that surrounds them and the absence of effective treatments.
To assist in individualized treatment, it is crucial to identify the factors that predict symptoms. However, the methods used to predict symptoms rely on clinical interview, which is not reliable and only detects a small number of symptoms associated with depression.2
Using machine learning to combine continuous digital behavioral phenotypes captured by smartphone sensors and a validated online mental health tracker (the Computerized Adaptive Testing Depression Inventory, CAT-DI) with other predictors of symptom severity can improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of unique behaviors and activity patterns that are difficult to record with interviews.
The study included University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA inpatient depression treatment centers Grand Challenge. Participants were sent online for support or clinical care according to the degree of their depression. Patients with a CAT DI score of 35 65 were given online support by an instructor and those with scores of 75 patients were referred to psychotherapy in person.
At the beginning of the interview, participants were asked the answers to a series of questions concerning their personal demographics and psychosocial characteristics. The questions covered age, sex and education, financial status, marital status, whether they were divorced or not, their current suicidal ideas, intent or attempts, and how depression is treated often they drank. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every week for those who received online support and weekly for those receiving in-person care.
Predictors of shock treatment for depression Reaction
A customized treatment for depression is currently a top research topic and many studies aim at identifying predictors that allow clinicians to identify the most effective drugs for each person. In particular, pharmacogenetics identifies genetic variations that affect the way that the body processes antidepressants. This lets doctors choose the medications that will likely work best for every patient, minimizing time and effort spent on trial-and error treatments and avoid any negative side effects.
Another promising approach is building models for prediction using multiple data sources, including clinical information and neural imaging data. These models can be used to determine the most appropriate combination of variables that are predictive of a particular outcome, like whether or not a drug is likely to improve symptoms and mood. These models can be used to determine the response of a patient to a treatment they are currently receiving, allowing doctors to maximize the effectiveness of the treatment currently being administered.
A new generation of studies utilizes machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have been proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming popular in psychiatry, and it is expected that they will become the standard for the future of clinical practice.
The study of depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that the disorder is linked with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for depression will be based on targeted therapies that restore normal functioning to these circuits.
Internet-delivered interventions can be a way to accomplish this. They can provide a more tailored and individualized experience for patients. For example, one study found that a web-based program was more effective than standard care in reducing symptoms and ensuring a better quality of life for those with MDD. In addition, a controlled randomized study of a customized treatment for depression demonstrated an improvement in symptoms and fewer adverse effects in a large number of participants.
Predictors of adverse effects
A major issue in personalizing depression treatment involves identifying and predicting the antidepressant medications that will have very little or no side effects. Many patients experience a trial-and-error method, involving several medications prescribed before finding one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting method to choose antidepressant drugs that are more efficient and targeted.
There are a variety of predictors that can be used to determine which antidepressant should be prescribed, such as gene variations, phenotypes of patients like gender or ethnicity and co-morbidities. However it is difficult to determine the most reliable and valid factors that can predict the effectiveness of a particular treatment will probably require randomized controlled trials of much larger samples than those typically enrolled in clinical trials. This is because it may be more difficult to identify moderators or interactions in trials that only include one episode per participant rather than multiple episodes over time.
Furthermore the prediction of a patient's response to a particular medication will also likely require information about the symptom profile and comorbidities, and the patient's personal experiences with the effectiveness and tolerability of the medication. Presently, only a handful of easily measurable sociodemographic and clinical variables appear to be correlated with the response to MDD factors, including age, gender race/ethnicity, SES, BMI and the presence of alexithymia and the severity of depressive symptoms.
There are many challenges to overcome in the application of pharmacogenetics in the treatment resistant depression treatment of depression. It is crucial to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an accurate definition of a reliable indicator of the response to treatment. In addition, ethical concerns, such as privacy and the appropriate use of personal genetic information, must be carefully considered. In the long term the use of pharmacogenetics could offer a chance to lessen the stigma that surrounds mental health care and improve treatment outcomes for those struggling with depression. However, as with all approaches to psychiatry, careful consideration and planning is essential. The best option is to offer patients various effective depression medications and encourage them to talk openly with their doctors about their concerns and experiences.
댓글목록 0